• Invest
    Investment Suite
    Stocks
    Mutual Funds
    Future and Options
    IPO
    Exchange Traded Funds
    Commodity
    Stockcase (Stock Baskets)
    Currency
    Non Convertible Debentures
    Sovereign Gold Bond
    Exclusive
    NRI Account
    Private Client Group
    Features
    SipIt
    MTF
    Investment Suite
    Exclusive
    Features
  • Platform
    Product Suite
    Kotak Neo App & Web
    Nest Trading Terminal
    NEO Trade APIs
    Features and Tools
    MTF
    Securities Accepted as Collateral
    Margin Requirements
    Payoff Analyzer
    Calculators
    SIP Calculator
    Lumpsum Calculator
    Brokerage Calculator
    Margin Calculator
    MTF Calculator
    All Calculators
    Product Suite
    Features and Tools
    Calculators
  • Pricing
  • Research
    Research Calls
    Long Term calls
    Short Term calls
    Intraday calls
    Derivatives calls
    Pick of the week
    Top Monthly Picks
    Research Reports
    Fundamental Research Report
    Technical Research Report
    Derivative Research Report
    Research Calls
    Research Reports
  • Market
    Stocks
    Market Movers
    Large Cap
    Mid Cap
    Small Cap
    Indices
    Nifty 50
    Bank Nifty
    FinNifty
    Nifty Midcap India
    VIX
    All Indian Indices
    Mutual Funds
    SBI Mutual Funds
    HDFC Mutual Funds
    Axis Mutual Funds
    ICICI Prudential Mutual Funds
    Nippon India Mutual Funds
    All AMC's
    IPO
    Upcoming IPO
    Current IPO
    Closed IPO
    Recently Listed IPO
    Stocks
    Indices
    Mutual Funds
    IPO
  • Learn
    Resource
    Market Ready
    Kotak Insights
    Infographic
    Podcast
    Webinars
    Youtube Channel
    Quarterly Results
    Investing Guide
    Demat Account
    Trading Account
    Share Market
    Intraday Trading
    IPO
    Mutual Funds
    Commodities
    Currency
    Futures & Options
    Derivatives
    Margin Trading
    Events
    Budget 2024
    Muhurat Trading
    Share Market Holiday
    Market Outlook 2024
    Resource
    Investing Guide
    Events
  • Partner
    Business Associates
    Fund Expert
    Kotak Connect Plus
    Startup connect
  • Support
    FAQs
    Circulars
    Bulletins
    Contact Us
    Forms Download
    Get your Statement
​

Emcure Pharmaceuticals Ltd IPO - Allocation Quota and Company Strategies

  •  3 min read
  • 0•
  • 0s ago
Emcure Pharmaceuticals Ltd IPO - Allocation Quota and Company Strategies

Key Highlights:

  • Emcure Pharma has plans to increase its market share in domestic markets
  • It plans to continue investing in R&D and manufacturing capabilities
  • Along with strategic acquisitions, it plans to deepen and expand its international presence

Emcure Pharmaceuticals Ltd is slated to launch its initial public offering (IPO) on 3rd July. The total issue size of Emcure Pharma IPO is Rs 1,952 crores at the upper price band. Like any IPO, the allocation quota has been fixed for different categories of investors. What are these and the company’s strategies going forward? Let’s find out.

The table shows the allocation quota of shares for different categories of investors:

Qualified Institutional Buyers (QIB) including Anchor

50%

96,33,084

971.01

Non-institutional Bidders (NIB)

15%

28,89,926

291.30

Bid above Rs 10 lakhs

19,26,618

194.20

Bid between Rs 2 lakhs to Rs 10 lakhs

9,63,308

97.10

Retail investors

35%

67,43,160

679.71

Employees

-

1,08,900

10

Category Allocation Number of shares at the upper price band Amount in Rs Crores at the upper price band
Qualified Institutional Buyers (QIB) including Anchor
50%
96,33,084
971.01
Non-institutional Bidders (NIB)
15%
28,89,926
291.30
Bid above Rs 10 lakhs
19,26,618
194.20
Bid between Rs 2 lakhs to Rs 10 lakhs
9,63,308
97.10
Retail investors
35%
67,43,160
679.71
Employees
-
1,08,900
10

As per the RHP, the company has the following strategies as a part of its expansion plan:

  • Increase market share in the domestic market

Emcure Pharma intends to consolidate its position and increase its market share in key and leading therapeutic areas, such as gynecology, cardiovascular, anti-infectives, HIV, blood-related, oncology/antineoplastic. It also intends to continue to enhance its position by leveraging its leadership position in key therapeutic areas to increase its market share in certain other therapeutic areas, such as neurology, anti-diabetics, respiratory and gastrointestinal.

  • Continue investing in R&D and manufacturing capabilities to grow its differentiated product portfolio

Emcure Pharma intends to continue investing in its R&D initiatives and further strengthening its manufacturing capabilities to grow its differentiated product portfolio for both the domestic and international markets. It also expects to continue investing in formulations and APIs for high-growth therapeutic areas.

The company intends to continue developing, and increasing our manufacturing capabilities for novel drug delivery systems. It also plans to continue developing its pipeline of biotherapeutics projects, which it intends to first launch in India and, subsequently, in various international markets.

  • Deepen and expand its international presence with a focused go-to-market approach

This is another future strategy of Emcure Pharma. It has filed over 1,800 dossiers globally for products offered through differentiated product platforms. It intends to continue growing its sales in all its target international markets by registering more of its products and increasing customer penetration. It also intends to continue focusing on technology-driven differentiated products, especially complex oral solids, injectables, and biotherapeutics.

  • Pursue strategic acquisitions, partnerships and in-licensing arrangements

Emcure Pharma, in the past, has made strategic acquisitions of companies, such as Tillomed Laboratories in the United Kingdom in 2014 and Marcan in Canada in 2015. It has recently strengthened our presence in the Quebec region of Canada through our acquisition of Mantra in November 2023. It intends to continue to pursue strategic acquisitions of company products and facilities across key markets.

It will be interesting to watch investors’ reaction to this IPO. Before investing, go through the company’s red herring prospectus for a complete overview and seek professional help if needed.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. It is not produced by the desk of the Kotak Securities Research Team, nor is it a report published by the Kotak Securities Research Team. The information presented is compiled from several secondary sources available on the internet and may change over time. Investors should conduct their own research and consult with financial professionals before making any investment decisions. Read the full disclaimer here.

Investments in securities market are subject to market risks, read all the related documents carefully before investing. Please read the SEBI prescribed Combined Risk Disclosure Document prior to investing. Brokerage will not exceed SEBI prescribed limit.

FAQs

The bid lot is 14 equity shares and in multiple of 14 equity shares thereafter.

Yes, the IPO has a fresh issue and an offer for sale. Fresh issue consists of equity shares worth Rs 800 crores while offer for sale is up to 1,14,28,839 equity shares.

Did you enjoy this article?

0 people liked this article.

What could we have done to make this article better?

Enjoy Free Demat Account Opening
+91 -

personImage
Enjoy Free Demat Account Opening
+91 -